Government Briefs

The White House Office of Science and Technology Policy is supposed to coordinate federal policy on science. But low-profile science adviser William Graham, even after 20 months on the job, occasionally still finds himself on the outside looking in. The latest snub is a new report from the Office of Technology Assessment on ways to improve U.S. efforts to commercialize high-temperature superconductivity [to get the report, call (202) 783-3238 and ask for GPO 052-003-01112-3; the price is $8].

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The White House Office of Science and Technology Policy is supposed to coordinate federal policy on science. But low-profile science adviser William Graham, even after 20 months on the job, occasionally still finds himself on the outside looking in. The latest snub is a new report from the Office of Technology Assessment on ways to improve U.S. efforts to commercialize high-temperature superconductivity [to get the report, call (202) 783-3238 and ask for GPO 052-003-01112-3; the price is $8]. In what passes for strong criticism on Capitol Hill, the soft-spoken Graham complained June 28 to the Senate Government Affairs Committee that “I wish my friend Dr. [John] Gibbons, [director] of OTA, had talked with me or other members of the OSTP” as they were working on the report. In comments after his testimony, Gibbons admitted that project director John Alic relied much more heavily on Defense Department and NSF officials than ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies